FDA Under Pressure On Its Approach To Assigning Combo Product Jurisdiction
This article was originally published in The Gray Sheet
Executive Summary
A federal court handed down a potentially significant ruling related to FDA’s policies for designating primary product review responsibility to the drug, biologic or device center just days after members of Congress questioned FDA on its approach.